Back to top
more

ANI Pharmaceuticals (ANIP)

(Delayed Data from NSDQ)

$59.20 USD

59.20
312,253

+0.25 (0.42%)

Updated Aug 14, 2024 04:00 PM ET

After-Market: $59.32 +0.12 (0.20%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Zacks.com featured highlights include: Assurant, Opera, ANI, eXp and Avista

Zacks.com featured highlights include: Assurant, Opera, ANI, eXp and Avista

Zacks.com featured highlights include: Assurant, Opera, ANI, eXp and Avista

Zacks.com featured highlights include: Assurant, Opera, ANI, eXp and Avista

Shrabana Mukherjee headshot

5 Stocks to Consider as New Analysts Initiate Coverage

Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.

ANI Pharmaceuticals (ANIP) Q2 Earnings Surpass Estimates

ANI (ANIP) delivered earnings and revenue surprises of 11.63% and -2.24%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Q2 Release

ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What Makes ANI (ANIP) a New Buy Stock

ANI (ANIP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

ANI Pharmaceuticals (ANIP) Dips More Than Broader Markets: What You Should Know

ANI Pharmaceuticals (ANIP) closed at $70.24 in the latest trading session, marking a -1.04% move from the prior day.

The Zacks Analyst Blog Highlights: Bed Bath & Beyond, ANI, DXP, Foot Locker and ACI

The Zacks Analyst Blog Highlights: Bed Bath & Beyond, ANI, DXP, Foot Locker and ACI

What's in Store for ANI Pharmaceuticals (ANIP) Q1 Earnings?

ANI Pharmaceuticals (ANIP) will provide updates on product launches, when it releases first-quarter 2019 results.

Tirthankar Chakraborty headshot

American Economy Hits the Gas: 5 Top Gainers

The U.S. economy grew 3.2% in the first quarter of 2019, primarily on two typically volatile components - inventories and trade.

Medicines Company (MDCO) Q1 Loss Narrows, Inclisiran in Focus

The Medicines Company (MDCO) suffers narrower-than-expected loss in Q1. The company progresses well with its sole pipeline candidate, inclisiran.

ANI Pharmaceuticals (ANIP) Dips More Than Broader Markets: What You Should Know

ANI Pharmaceuticals (ANIP) closed at $69.66 in the latest trading session, marking a -0.49% move from the prior day.

Alexion (ALXN) Q1 Earnings Beat Estimates, Guidance Raised

Alexion (ALXN) beats earnings and sales estimates in the first quarter of 2019 and raises guidance for the year.

Zacks.com featured expert Kevin Matras highlights: Advanced Emissions Solutions, Verint Systems, Great Lakes Dredge & Dock, ANI Pharmaceuticals and ACI Worldwide

Zacks.com featured expert Kevin Matras highlights: Advanced Emissions Solutions, Verint Systems, Great Lakes Dredge & Dock, ANI Pharmaceuticals and ACI Worldwide

Nalak Das headshot

5 Stocks With Recent Price Strength to Enhance Your Returns

Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

ANI Pharmaceuticals (ANIP) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, ANI Pharmaceuticals (ANIP) closed at $68.88, marking a -0.17% move from the previous day.

Ultragenyx's (RARE) UX007 Gets Fast Track Status by FDA

Ultragenyx???s (RARE) UX007 receives Fast Track designation and Rare Pediatric Disease designation by the FDA for the treatment of long-chain fatty acid oxidation disorders.

QIAGEN Drives Molecular Diagnostics Suite With New Test Kit

QIAGEN (QGEN) introduces the FDA approved companion diagnostic test to help in guiding therapy in any cancer identification.

Has ANI Pharmaceuticals (ANIP) Outpaced Other Medical Stocks This Year?

Is (ANIP) Outperforming Other Medical Stocks This Year?

3 Reasons Why Growth Investors Shouldn't Overlook ANI (ANIP)

ANI (ANIP) could produce exceptional returns because of its solid growth attributes.

ANI Pharmaceuticals (ANIP) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, ANI Pharmaceuticals (ANIP) closed at $69.44, marking a +1.71% move from the previous day.

Moumita Chattopadhyay headshot

5 Stocks With Increasing Cash Flows to Scoop Up Big Gains

Cash gives a company vitality and strength. It holds the key to its existence, development and success, and can indeed be referred to as its lifeblood.

Zacks.com featured expert Kevin Matras highlights: Herc, ANI Pharmaceuticals, Kamada, SP Plus and SkyWest

Zacks.com featured expert Kevin Matras highlights: Herc, ANI Pharmaceuticals, Kamada, SP Plus and SkyWest

BioDelivery (BDSI) Buys US Rights to Pain Drug for $30M

BioDelivery Sciences (BDSI) announces acquisition of U.S. commercial rights to pain drug, Symproic, from Japanese company, Shinogi.

Tap These 6 Stocks That Flaunt Sizeable Net Profit Margin

Here are six stocks with spectacular net profit margins that investors can bank on for stellar returns.